Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2016 07:35 ET | Source: Neuralstem, Inc.

Neuralstem Reports Third Quarter 2016 Results

GERMANTOWN, Md., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem...
November 02, 2016 07:35 ET | Source: Neuralstem, Inc.

Neuralstem Announces Presentations at Upcoming Scientific Conferences

GERMANTOWN, Md., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural...
October 20, 2016 07:52 ET | Source: Neuralstem, Inc.

Neuralstem Presents NSI-189 Preclinical Neurocognitive Benefits at the Radiation Research Society Annual Meeting

GERMANTOWN, Md., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem...
September 21, 2016 08:32 ET | Source: Neuralstem, Inc.

Neuralstem Achieves 50% Enrollment in NSI-189 Phase 2 Trial in Major Depressive Disorder

GERMANTOWN, Md., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural...
September 13, 2016 01:11 ET | Source: Neuralstem, Inc.

Neuralstem获Tianjin Pharmaceutical Group 20,000,000美元的战略性投资

美国马里兰州日耳曼敦, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc.（纳斯达克：CUR）今日宣布其于2016年9月7日与Tianjin Pharmaceutical Holding Group订立一份最终协议，同意私人配售总金额为20,000,000美元的普通股和可转换优先股。Neuralstem,...
September 12, 2016 08:32 ET | Source: Neuralstem, Inc.

Neuralstem Presented NSI-189 Preclinical Data in Type 1 and Type 2 Diabetes at the Annual Meeting of the Diabetic Neuropathy Study Group

GERMANTOWN, Md., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural...
September 12, 2016 08:03 ET | Source: Neuralstem, Inc.

Neuralstem Receives $20,000,000 Strategic Investment from Tianjin Pharmaceutical Group

GERMANTOWN, Md., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem...
August 11, 2016 16:05 ET | Source: Neuralstem, Inc.

Neuralstem Reports Second Quarter 2016 Results and Provides Business and Clinical Updates

GERMANTOWN, Md., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural...
June 21, 2016 08:15 ET | Source: Neuralstem, Inc.

Neuralstem Announces NSI-189 Shows Enhancement of Long-Term Potentiation In Vitro

GERMANTOWN, Md., June 21, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural...
June 13, 2016 08:45 ET | Source: Neuralstem, Inc.

Neuralstem Announces New Chairman and Further Reorganization Plans

GERMANTOWN, Md., June 13, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural...